Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252057 · ClinicalTrials.gov registry record · NA
Testing the Re-Engineered Hospital Discharge
A NA study, sponsored by Boston University.
- Completed
- Registry status
- NA
- Development phase
- 749
- Enrollment target
NCT00252057: Completed NA study, sponsored by Boston University.
NCT00252057 is a NA study that has completed, run by Boston University. The registered enrollment target is 749 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00252057, a NA study, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- NA
- Development phase
- 749 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the "Re-Engineered Discharge" will decrease rehospitalization rates and adverse events of patients leaving Boston Medical Center.
Primary Outcome
The total number of rehospitalizations (emergency department visits plus hospital admissions) in the 30 days after discharge, compared across study arms. Participants could have more than one rehospitalization in this period; all rehospitalizations for each were counted, making the unit of measure the rehospitalizations and not the participants.
Interventions
- BEHAVIORAL Re-Engineered Hospital Discharge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 749 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-10 |
| Phase | NA |
What the finished NCT00252057 record still lists
NCT00252057 is an interventional study that assigns participants to a tested intervention. The registered 749 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Re-Engineered Hospital Discharge is the first listed.
NCT00252057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00252057 about?
NCT00252057 is a clinical study titled "Testing the Re-Engineered Hospital Discharge". The purpose of this study is to determine if the "Re-Engineered Discharge" will decrease rehospitalization rates and adverse events of patients leaving Boston Medical Center.
What is the current status of trial NCT00252057?
This trial is currently completed. It is a NA study. The enrollment target is 749 participants. The study started on 2005-12. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00252057?
The interventions under investigation include: Re-Engineered Hospital Discharge (BEHAVIORAL).
Who is sponsoring clinical trial NCT00252057?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00252057's enrollment target sits among peer trials
749 145th of 2000 higher than 1,856 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia